RESUMEN
Buccal bioadhesive tablet formulations of nicotine hydrogen tartrate (NHT) for nicotine replacement therapy (NRT) were developed using chitosan and carbomer at different ratios. Magnesium hydroxide was incorporated into the formulations as pH increasing agent. In vitro release and bioadhesion properties of the tablets were investigated. Release of NHT from the tablets was increased with the increasing amount of chitosan in formulations whilst the bioadhesion of the tablet was decreased. In vivo studies were carried out in healthy, non-smoker volunteers in comparison to a commercially available transdermal patch. Plasma nicotine and cotinine levels were determined using gas chromatography-mass spectrophotometry. No significant difference was found between the maximum plasma nicotine concentrations (Cmax) obtained with the buccal tablet and the transdermal patch (p > 0.05). Time to reach the Cmax was 2.9 +/- 0.2 h and 11.5 +/- 1.3 h, and AUC0-24 values were 59.3 +/- 5.1 ng x h x mL(-1) (0-12 h) and 204.1 +/- 31.2 ng x h x mL(-1) for buccal tablet and transdermal patch, respectively.
Asunto(s)
Nicotina/administración & dosificación , Agonistas Nicotínicos/administración & dosificación , Cese del Hábito de Fumar , Resinas Acrílicas , Adhesividad , Adhesivos , Adulto , Química Farmacéutica , Quitosano , Cotinina/sangre , Formas de Dosificación , Femenino , Humanos , Cinética , Hidróxido de Magnesio/química , Masculino , Mucosa Bucal , Nicotina/sangre , Nicotina/uso terapéutico , Agonistas Nicotínicos/sangre , Agonistas Nicotínicos/uso terapéutico , SolubilidadRESUMEN
Bioadhesive buccal tablet formulations for delivery of nicotine into the oral cavity were developed. Carbomer (Carbopol)974P NF) (CP) and alginic acid sodium salt (NaAlg) were used as bioadhesive polymers in combination with hydroxypropyl methylcellulose (HPMC) at different ratios. Magnesium carbonate was incorporated into the formulations as a pH increasing agent. In vitro release and bioadhesion studies were performed on the developed tablets. In the formulations containing CP:HPMC, the NHT released increased with the increasing HPMC concentration whereas a decrease was observed with increasing HPMC concentration in formulations containing NaAlg:HPMC. The bioadhesive properties of the tablets containing NaAlg:HPMC was not affected by the concentration of the NaAlg (P>0.05) but increased significantly with the increasing CP concentration (P>0.05). A decrease in pH of the dissolution medium to acidic values was avoided by incorporation of magnesium hydroxide into the formulations. The developed formulations released NHT for 8h period, and remained intact except for the formulation containing CP:HPMC at 20:80 ratio.
Asunto(s)
Mucosa Bucal/metabolismo , Nicotina/farmacocinética , Cese del Hábito de Fumar/métodos , Adhesivos , Administración Bucal , Animales , Bovinos , Química Farmacéutica , Cámaras de Difusión de Cultivos/métodos , Técnicas In Vitro , Mucosa Bucal/efectos de los fármacos , Nicotina/administración & dosificación , ComprimidosRESUMEN
Local delivery systems of antimicrobial agents for treatment of the periodontal diseases received considerable attention during the past decade due to the disadvantages of the systemic administration. An ideal formulation should exhibit ease of delivery, a good retention at the application site, and a controlled release of the drug. The application of bioadhesive gels provides a long stay in the oral cavity, adequate drug penetration, high efficacy and acceptability. In dentistry and oral medicine, various applications of chitosan, which is a bioadhesive polymer have been proposed due to its favorable properties such as biocompatibility and biodegradability. The aim of this study was to determine the antimicrobial activity of chitosan formulations either in gel or film form against a periodontal pathogen, Porphyromonas gingivalis. The viscosity, bioadhesive properties and antimicrobial activity of chitosans at different molecular weight and deacetylation degree were evaluated in the absence or presence of chlorhexidine gluconate (Chx), incorporated into the formulations at 0.1 and 0.2% concentrations. The flow property of the gels were found to be suitable for topical application on the oral mucosa and to syringe into the periodontal pocket. Bioadhesion of the gels and films examined ex-vivo using fresh porcine buccal mucosa showed that both the film and gel formulations exert bioadhesive properties and was not affected by incorporation of Chx. Chitosan is shown to have an antimicrobial activity against P. gingivalis and this was higher with high molecular weight chitosan. The combination of chitosan with Chx showed a higher activity when compared to that of Chx alone, which would provide Chx application at lower concentrations thus avoiding its unwanted side effects. Chitosan films and gels seem to be promising delivery systems for local therapy of periodontal diseases with its bioadhesive property and antimicrobial activity.
Asunto(s)
Antibacterianos/administración & dosificación , Infecciones por Bacteroidaceae/microbiología , Quitina/administración & dosificación , Clorhexidina/análogos & derivados , Enfermedades Periodontales/microbiología , Porphyromonas gingivalis/efectos de los fármacos , Antibacterianos/química , Adhesión Bacteriana/efectos de los fármacos , Infecciones por Bacteroidaceae/tratamiento farmacológico , Quitina/análogos & derivados , Quitina/química , Quitosano , Clorhexidina/administración & dosificación , Clorhexidina/química , Sistemas de Liberación de Medicamentos/métodos , Evaluación Preclínica de Medicamentos/métodos , Geles , Humanos , Enfermedades Periodontales/tratamiento farmacológico , Porphyromonas gingivalis/crecimiento & desarrollo , ViscosidadRESUMEN
A buccoadhesive controlled-release system for delivery of carbamazepine (CBZ) was prepared by compression of hydroxypropyl methylcellulose (HPMC) and carbomer, incorporating a penetration enhancer, sodium glycodeoxycholate (GDC). The release behaviour of systems containing CBZ and various amounts of the two polymers with and without GDC was found to be non-Fickian. Formation of an interpolymer complex between HPMC and carbomer was confirmed in acidic medium by turbidity, viscosity and FT-IR measurements. Addition of the drug to the buccoadhesive formulation reduced the adhesion force significantly (p < 0.1). GDC did not have any effect on bioadhesion. Permeability of bovine buccal mucosa to CBZ was determined using Ussing diffusion chambers [1]. In vivo interaction between the tablet and tissue was examined histologically as well as by scoring mucosal irritation. Histological changes observed in the buccal epithelium after 4 h contact with the tablets containing GDC recovered completely within 24 h after removal. No measurable plasma level of CBZ was obtained either in the absence or presence of GDC.
Asunto(s)
Anticonvulsivantes/administración & dosificación , Carbamazepina/administración & dosificación , Mucosa Bucal/metabolismo , Absorción , Adhesivos , Adulto , Animales , Anticonvulsivantes/efectos adversos , Anticonvulsivantes/farmacocinética , Carbamazepina/efectos adversos , Carbamazepina/farmacocinética , Bovinos , Femenino , Humanos , Técnicas In Vitro , Irritantes , Cinética , Lactosa/análogos & derivados , Masculino , Metilcelulosa/análogos & derivados , Oxazinas , Solubilidad , ComprimidosRESUMEN
Topical delivery of antimicrobial agents is the most widely accepted approach aimed at prolonging active drug concentrations in the oral cavity. As most antifungals do not posses inherent ability to bind to the oral mucosa, this is best achieved through improved formulations. Chitosan, a partially deacetylated chitin, which is a biologically safe biopolymer, prolongs the adhesion time of oral gels and drug release from them. Chitosan also inhibits the adhesion of Candida albicans to human buccal cells and has antifungal activity. The antifungal agent, chlorhexidine gluconate (Chx), also reduces C. albicans adhesion to oral mucosal cells. The aim of this study was to design a formulation containing chitosan for local delivery of Chx to the oral cavity. Gels (at 1 or 2% concentration) or film forms of chitosan were prepared containing 0.1 or 0.2% Chx and their in vitro release properties were studied. The antifungal activity of chitosan itself as well as the various formulations containing Chx was also examined. Release of Chx from gels was maintained for 3 h. A prolonged release was observed with film formulations. No lag-time was observed in release of Chx from either gels or films. The highest antifungal activity was obtained with 2% chitosan gel containing 0.1% Chx.
Asunto(s)
Quitina/análogos & derivados , Clorhexidina/análogos & derivados , Excipientes/química , Hidrogeles/química , Antisépticos Bucales/administración & dosificación , Absorción , Adhesividad , Administración Oral , Candida albicans/efectos de los fármacos , Quitina/química , Quitosano , Clorhexidina/administración & dosificación , Clorhexidina/química , Clorhexidina/farmacología , Preparaciones de Acción Retardada , Pruebas de Sensibilidad Microbiana , Microscopía Electrónica de Rastreo , Mucosa Bucal , Antisépticos Bucales/química , Antisépticos Bucales/farmacología , Solubilidad , Propiedades de Superficie , ViscosidadRESUMEN
Carbamazepine controlled-release tablet formulations containing hydroxypropyl methylcellulose (HPMC) as matrix material at different concentrations were developed and evaluated in vitro and in vivo. The formulation containing 10% HPMC (HPMC-10) showed a controlled-release profile comparable to that of a commercially available, controlled-release carbamazepine preparation (Tegretol CR 200). The kinetics of controlled-release carbamazepine tablets was examined in eight healthy volunteers. The peak plasma concentration of 1.99 +/- 0.56 micrograms.ml-1 was obtained for HPMC-10 at 15.0 +/- 9.0 h, and 1.33 +/- 0.35 micrograms.ml-1 for Tegretol CR 200 at 15.2 +/- 8.9 h, and AUC0-infinity values of 85.2 +/- 30.8 micrograms.h.ml-1 and 76.9 +/- 20.7 micrograms.h.ml-1, respectively. Developed formulation (HPMC-10) was found to be bioequivalent to Tegretol CR 200 and, controlled release was obtained with smoother concentration-time curve resulting in less fluctuations.